SCHEMBL20595979

SCHEMBL20595979

NC(=O)Cn1c(C(=O)c2ccc(Cl)cc2Cl)cn(Cc2nc3nc(Cl)ccc3[nH]2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 7/20 0.56
▸ CHEK2 O96017 1/20 0.34
▸ KMT2A Q03164 3/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ P2RX3 P56373 2/20 0.31
▸ POLB P06746 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ SIRT1 Q96EB6 1/20 0.31
▸ P2RX7 Q99572 1/20 0.31
▸ GRIN2B Q13224 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30
▸ MPO P05164 1/20 0.30
▸ TPO P07202 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595905 0.92 MARS2 (0.56) MARS2KMT2ASMN1; SMN2MEN1HSD17B10
SCHEMBL20595861 0.90 MARS2 (0.67) MARS2CHEK2KMT2ASMN1; SMN2MEN1
SCHEMBL20595919 0.88 MARS2 (0.56) MARS2KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL20596131 0.88 MARS2 (0.56) MARS2KMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL23419466 0.86 MARS2 (0.40) MARS2CHEK2KMT2ASMN1; SMN2MEN1
SCHEMBL20595944 0.83 MARS2 (0.51) MARS2SMN1; SMN2HSD17B10
SCHEMBL20595871 0.80 MARS2 (0.70) MARS2ALDH1A1POLBKDM4E
SCHEMBL20596584 0.79 MARS2 (0.52) MARS2CHEK2KMT2ASMN1; SMN2MEN1
SCHEMBL20595943 0.79 MARS2 (0.48) MARS2SMN1; SMN2HSD17B10
SCHEMBL23391426 0.76 MARS2 (0.49) MARS2CHEK2KMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO claimed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885CHEK2 3886/4885KMT2A 1475/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885CHEK2 3554/4885KMT2A 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback